Prenostics

1 known investors

Prenostics develops a blood test to detect the earliest stages of cancer (stages 0-2), earlier than current methods, aiming to enable curative treatment. Its initial clinical targets are women at elevated risk of ovarian cancer and people with indeterminate lung nodules.

BiotechDigital HealthHealthtech